Integrated Care Protocol: Prevention, diagnosis and treatment of diabetes mellitus 2
Main Article Content
Keywords
Clinical Protocols, Organization and Administration, Diagnosis, Preventive Health Services, Diabetes Mellitus, Type 2
Abstract
Background: Type 2 diabetes mellitus (DM2) represents one of the ten non- transmissible chronic diseases that constitute the main causes of death and disability in Mexico. It is the leading cause of disability and the second cause of death. The IMSS serves 4.2 million people living with this disease.
Objective: Establish lines of action that allow standardizing the substantive activities to be carried out by the multidisciplinary health team, promoting healthy lifestyles, establishing timely diagnoses, providing adequate and intensified care and treatments, preventing complications, and providing comprehensive care and of quality for the benefit of the beneficiaries.
Methods: The process of development of the Integrated Care Protocols consisted of: 1) Prioritization of the health problem, 2) Conformation of an interdisciplinary work group, 3) Development of content and systematic search for information 4) Analysis, review and discussion of interventions, 5) Review and validation by regulatory areas, 6) Dissemination and implementation.
Conclusions: Promotion and prevention actions must be carried out at all levels and by all health personnel, likewise, the incorporation of new treatments for DM2 in the IMSS, requires the homologation of the criteria in risk stratification, diagnosis, profile risk of hypoglycemia and adverse effects to limit the complications of the disease and reduce the burden of disease (disability and premature death).
References
Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha-Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes ResClin Pract. 2018;138:271-281.
Organización Mundial de la Salud. Informe Mundial sobre la Diabetes. Resumen de Orientación. Ginebra, Suiza: World Health Organization; 2016.
OECD. Health at a Glance 2017: OECD Indicators. Paris: OECD Publishing; 2017. Disponible en: https://doi.org/10.1787/19991312
González-León M, Fernández-Gárate J, Hernández-Cuesta I, Medina-Reyes I, Morales-Valdez X, Torres-Rojas N, et al. Carga de las Enfermedades en el IMSS, 2015. Ciudad de México, México: Coordinación de Vigilancia Epidemiológica, Instituto Mexicano del Seguro Social; 2018.
Ruiz-Matus C, Gaona-Pineda E, Méndez-Gómez-Humarán I, Cuevas-Nasu L, Gómez-Acosta L, Jiménez-Corona M, et al. ENSANUT Encuesta Nacional de Salud y Nutrición de Medio Camino 2016. Informe Final de Resultados. Cuernavaca, Morelos: Instituto Nacional de Salud Pública; 2016.
American Diabetes Association. Lifestyle Management: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S46-S60
Red de Grupos de Estudio de la Diabetes en Atención Primaria de la Salud. Guía de Actualización en Diabetes Mellitus tipo 2. Badalona, España: Fundación RedGDPS; 2016.
Instituto Mexicano del Seguro Social. Dirección de Prestaciones Médicas. Procedimiento para la operación y acciones de promoción de la salud PREVENIMSS. 2210-B03-03. Ciudad de México, México: IMSS; 2012.
Martínez-Brocca MA. Diabetes Mellitus: proceso asistencial integrado. 3ª edición, Sevilla, España: Consejería de Salud. Junta de Andalucía; 2018.
Bickerdike L, Booth A, Wilson PM, Farley K, Wright K. Social prescribing: less rhetoric and more reality. A systematic review of the evidence. BMJ Open. 2017;7(4):e013384.
American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S14-S31. doi: 10.2337/dc20-S002.
Juan Rosas-Saucedo, A. Enrique Caballero, Griselda Brito-Córdova, Hernán García-Bruce, José Costa-Gil, Lyra R, et al. Consenso de Prediabetes. Documento de posición de la Asociación Latinoamericana de Diabetes (ALAD). Rev ALAD. 2017;7:184-202. doi: 10.24875/ALAD.17000307
Ministry of Public Health. Clinical Guidelines for the State of Qatar. The diagnosis and management of type 2 diabetes in adults and the elderly. December 2017.
KDIGO. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Inter. 2013;3:1-150.
Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825‐830.
American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S111-S134. doi: 10.2337/dc20-S010.
American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S66-S76.
American Diabetes Association. 12. Older Adults: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S152-S162.
LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(5):1520-1574.
Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-2381.
Alvarez S, Coffey R, Algotar AM. Prediabetes. 2020 Jul 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020.
American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43 (Suppl 1):S98-S110. doi: 10.2337/dc20-S009.
Chaudhury A, Duvoor C, Reddy Dendi VSR, Kraleti S, Chada A, et al. Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. Front Endocrinol (Lausanne). 2017;8:6.
Garber AJ, Handelsman Y, Grunberger G, Einhorn E, Abrahamson MJ, Barzilay JI, et al. Consensus Statement by the American Association of Clinical Endocrinologist and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm. Endocrine Practice. 2019;25(1):69-100.
Gilbert RE. SGLT2 inhibitors: β blockers for the kidney? Lancet Diabetes Endocrinol. 2016;4(10):814.